Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment

Chen Li1 12 2,* Long Wan1 12 2,* Jie Luo1 12 2, Mingyan Jiang1 12 2, Keke Wang1 12 2 1Department of Pharmacy, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China; 2School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, P...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li C, Wan L, Luo J, Jiang M, Wang K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	diabetes mellitus subcutaneous injection insulin glucagon-like peptide 1 receptor agonists sustained-release stimuli-responsive Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4aa5482d9ff0499ea7b5d95e30e82abb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4aa5482d9ff0499ea7b5d95e30e82abb
record_format	dspace
spelling	oai:doaj.org-article:4aa5482d9ff0499ea7b5d95e30e82abb2021-12-02T14:40:57ZAdvances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment1178-2013https://doaj.org/article/4aa5482d9ff0499ea7b5d95e30e82abb2021-02-01T00:00:00Zhttps://www.dovepress.com/advances-in-subcutaneous-delivery-systems-of-biomacromolecular-agents--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Chen Li1 12 2,* Long Wan1 12 2,* Jie Luo1 12 2, Mingyan Jiang1 12 2, Keke Wang1 12 2 1Department of Pharmacy, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China; 2School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Keke WangDepartment of Pharmacy, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, People’s Republic of ChinaTel +86-24-83282662Email wkkcc@163.comAbstract: Diabetes mellitus is a major threat to human health. Both its incidence and prevalence have been rising steadily over the past few decades. Biomacromolecular agents such as insulin and glucagon-like peptide 1 receptor agonists are commonly used hypoglycemic drugs that play important roles in the treatment of diabetes. However, their traditional frequent administration may cause numerous side effects, such as pain, infection or local tissue necrosis. To address these issues, many novel subcutaneous delivery systems have been developed in recent years. In this review, we survey recent developments in subcutaneous delivery systems of biomacromolecular hypoglycemic drugs, including sustained-release delivery systems and stimuli-responsive delivery systems, and summarize the advantages and limitations of these systems. Future opportunities and challenges are discussed as well.Keywords: diabetes mellitus, subcutaneous injection, insulin, glucagon-like peptide 1 receptor agonists, sustained-release, stimuli-responsiveLi CWan LLuo JJiang MWang KDove Medical Pressarticlediabetes mellitussubcutaneous injectioninsulinglucagon-like peptide 1 receptor agonistssustained-releasestimuli-responsiveMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 1261-1280 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes mellitus subcutaneous injection insulin glucagon-like peptide 1 receptor agonists sustained-release stimuli-responsive Medicine (General) R5-920
spellingShingle	diabetes mellitus subcutaneous injection insulin glucagon-like peptide 1 receptor agonists sustained-release stimuli-responsive Medicine (General) R5-920 Li C Wan L Luo J Jiang M Wang K Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
description	Chen Li1 12 2,* Long Wan1 12 2,* Jie Luo1 12 2, Mingyan Jiang1 12 2, Keke Wang1 12 2 1Department of Pharmacy, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China; 2School of Pharmacy, China Medical University, Shenyang, 110122, Liaoning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Keke WangDepartment of Pharmacy, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, People’s Republic of ChinaTel +86-24-83282662Email wkkcc@163.comAbstract: Diabetes mellitus is a major threat to human health. Both its incidence and prevalence have been rising steadily over the past few decades. Biomacromolecular agents such as insulin and glucagon-like peptide 1 receptor agonists are commonly used hypoglycemic drugs that play important roles in the treatment of diabetes. However, their traditional frequent administration may cause numerous side effects, such as pain, infection or local tissue necrosis. To address these issues, many novel subcutaneous delivery systems have been developed in recent years. In this review, we survey recent developments in subcutaneous delivery systems of biomacromolecular hypoglycemic drugs, including sustained-release delivery systems and stimuli-responsive delivery systems, and summarize the advantages and limitations of these systems. Future opportunities and challenges are discussed as well.Keywords: diabetes mellitus, subcutaneous injection, insulin, glucagon-like peptide 1 receptor agonists, sustained-release, stimuli-responsive
format	article
author	Li C Wan L Luo J Jiang M Wang K
author_facet	Li C Wan L Luo J Jiang M Wang K
author_sort	Li C
title	Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
title_short	Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
title_full	Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
title_fullStr	Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
title_full_unstemmed	Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
title_sort	advances in subcutaneous delivery systems of biomacromolecular agents for diabetes treatment
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/4aa5482d9ff0499ea7b5d95e30e82abb
work_keys_str_mv	AT lic advancesinsubcutaneousdeliverysystemsofbiomacromolecularagentsfordiabetestreatment AT wanl advancesinsubcutaneousdeliverysystemsofbiomacromolecularagentsfordiabetestreatment AT luoj advancesinsubcutaneousdeliverysystemsofbiomacromolecularagentsfordiabetestreatment AT jiangm advancesinsubcutaneousdeliverysystemsofbiomacromolecularagentsfordiabetestreatment AT wangk advancesinsubcutaneousdeliverysystemsofbiomacromolecularagentsfordiabetestreatment
_version_	1718390049758773248

Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment

Ejemplares similares